Imugene Ltd

IMU

Company Profile

  • Business description

    Imugene Ltd is an Australian-headquartered clinical stage cell therapy company developing an Allogeneic CAR T for blood cancers. Its lead asset is an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. The lead asset, azer-cel, is an allogeneic CAR T cell therapy targeting CD19 positive cancer cells. Autologous CAR T therapies, which use the patient's own modified T cells, azer-cel uses donor-derived T cells that are genetically engineered to attack cancer cells. The group has identified one reportable segment, being the research and development of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours.

  • Contact

    4-6 Bligh Street
    Suite 12.01, Level 12
    SydneyNSW2000
    AUS

    T: +61 294230881

    https://www.imugene.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    Employees

    5

Stocks News & Analysis

stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.
stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,165.4039.10-0.42%
CAC 408,352.0016.91-0.20%
DAX 4026,598.64151.31-0.57%
Dow JONES (US)51,608.17739.38-1.41%
FTSE 10010,881.5521.01-0.19%
HKSE23,753.84116.240.49%
NASDAQ24,509.76626.52-2.49%
Nikkei 22559,662.021,480.33-2.42%
NZX 50 Index14,260.8542.92-0.30%
S&P 5007,416.59145.08-1.92%
S&P/ASX 2009,044.7037.50-0.41%
SSE Composite Index3,602.5731.78-0.87%

Market Movers